VivoSeq
Oncology

Brain Tumor

5

Pipeline Programs↗

9

Active Trials↗

3

Companies Involved↗

Brain Tumor is an early-stage landscape with 5 programs across 3 companies. The most active players are Novartis, Viatris Specialty LLC, Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

35/100

Pipeline Velocity

15/100

Mech. Concentration

33/100

Completion Rate

92/100

Attrition Rate

4/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

Phase 1V

Viatris Specialty LLC

1 program

Phase 1Eli Lilly logo

Eli Lilly

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

75%

Small molecule

3 of 4 classified programs — the dominant modality here.

25%ALL OTHERSProtein / enzyme125%

Small molecule leads; the ring shows all 4 classified programs, each share of the total. Modality classified for 80% of 5 pipeline programs.

Analysis

Trial Status

23

clinical trials

Completed11 · 48%
Recruiting5 · 22%
Unknown status2 · 9%
Not yet recruiting2 · 9%
Active, not recruiting2 · 9%
Terminated1 · 4%

Clinical Trials

Trial Activity

23 trials

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
Recruiting·Children's Oncology Group·Phase 2·NCT04684368·160 enrolled
A Phase IV and Observational Study to Evaluate Safety and Effectiveness of Temozolomide (Amitzo, NanoAlvand) Therapy in in Patients With Grade III and IV Glioma Tumors
Recruiting·NNanoAlvand·N/A·NCT07675070·100 enrolled
Phase 1/Phase 2, Open Label Study Evaluating the Safety, Dosing and Efficacy of Panitumumab IRDye800 as an Optical Imaging Agent to Detect Pediatric Neoplasms During Neurosurgical Procedures
Recruiting·SStanford University·Preclinical·NCT04085887·12 enrolled
Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients
Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Preclinical·NCT05658731·338 enrolled
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
Recruiting·National Cancer Institute (NCI)·Preclinical·NCT05588141·96 enrolled
A Phase 2 Study of Abemaciclib in Patients With Recurrent Primary Brain Tumors
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03220646·64 enrolled
Biological Substrates of Impaired Neurocognitive Functioning: Understanding the Late Effects of Surviving a Pediatric Brain Tumor
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·N/A·NCT03208387·42 enrolled
Levetiracetam Prophylaxis in Brain Tumor Resection Pilot
Not yet recruiting·HHamilton Health Sciences Corporation·Phase 3·NCT05897658·70 enrolled
An Early Phase 1 Study of Asciminib With or Without Sildenafil for Brain Tumors
Not yet recruiting·WWashington University School of Medicine·Phase 1·NCT07039760·12 enrolled
Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor
Completed·WWake Forest University Health Sciences·Phase 2·NCT00070161·68 enrolled
Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor
Completed·—·Phase 1·NCT00069940
Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor
Completed·TTocagen Inc.·Phase 1·NCT01985256·17 enrolled
Phase IV Bioseal Study in Brain Tumor Surgery
Completed·EEthicon, Inc.·Phase 4·NCT02034799·256 enrolled
Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor
Completed·TTocagen Inc.·Phase 1·NCT01470794·58 enrolled
Improving Ultrasound Images in Brain Tumor Surgery With the Use of Brain Mimicking Fluid
Completed·SSt. Olavs Hospital·Phase 1·NCT02105233·15 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)